Ipsos Vantis surveyed 125 physicians to gauge their prior knowledge and receptivity to Qnexa. This concept was compiled using publicly available sources and this research was not specifically commissioned by any company. This presents our views and analysis of Qnexa receptivity in the U.S. market.
1. Vantis Health Files
Qnexa (phentermine and
topiramate) for Obesity
Companies referenced in this Report:
Abbott Laboratories
Arena Pharmaceuticals
Orexigen Therapeutics
Roche Pharmaceuticals
Vivus, Inc.
For More Information, Contact:
Thomas B. Young
Direct: 973.658.1686
Mobile: 201-755-6096
Tom.Young@ipsos.com
Sept 16, 2010 Linking Market Research to Market Performance